Irbesartán Aurovitas (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition reduces vasoconstriction, aldosterone release, and sympathetic activation, leading to relaxation of blood vessels, decreased sodium‑water retention, and lower blood pressure. The renal protective effect arises from reduced intraglomerular pressure.

The exact dose of Irbesartán Aurovitas is determined by the prescribing clinician based on the patient’s blood‑pressure readings, kidney function, and overall health status. Dosage adjustments may be required during therapy, and the prescriber will provide individualized instructions.

Safety of irbesartan in pregnancy has not been established, and the drug is generally avoided because it may affect fetal renal development. Limited data are available for breastfeeding; therefore, the medication should only be used if the potential benefit outweighs the risk and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the angiotensin II receptor blocker class, offering blood‑pressure control comparable to ACE inhibitors but with a lower incidence of cough. Compared with calcium‑channel blockers, it provides additional renal protection in diabetic patients, while its safety profile is generally well‑tolerated.

Irbesartán Aurovitas should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse reactions, although rare, include angioedema, severe hypotension, acute kidney injury, and significant hyperkalaemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, marked weakness, or a rapid decline in kidney function.

Irbesartán Aurovitas is contraindicated in patients with known hypersensitivity to irbesartan or any component of the formulation, and it should be avoided in individuals with severe hepatic impairment or in pregnant women. Caution is also advised for patients with existing renal dysfunction or elevated serum potassium.